Bionano Genomics Sees 21% Revenue Growth in Q3 2025

In the third quarter of 2025, Bionano Genomics, Inc. reported strong financial results, with total revenue increasing 21% compared to the same period in 2024. The company's focus on supporting and expanding its existing user base, rather than aggressively growing its installed base, appears to be paying off.

Bionano Genomics is transforming pathology, the medical discipline that investigates disease, by transitioning it from an analog past to a digital future. The company's digital pathology solutions include optical genome mapping systems, the IONIQ system for nucleic acid isolation, and its VIA software. These solutions aim to simplify workflows and address significant unmet needs in cytogenetics and molecular pathology.

The company's CEO, Erik Holmlin, highlighted that Bionano is executing on four strategic pillars to drive growth: supporting and sustaining its installed base of routine users, driving utilization through software adoption, building support for optical genome mapping reimbursement, and improving profitability and scalability. In Q3 2025, the company achieved solid gross margins, remained disciplined with operating expenses, and increased utilization from its routine users, who are characterized by having an established flow of samples coming into their labs.